GlassScriptPhysician profile
Babak B Abrishami
NPI 1972553576
$1,126.91
in general payments reported to CMS, 2019-2025
11 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.30 · 2020: $12.45 · 2021: $151 · 2022: $224 · 2023: $203 · 2024: $337 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $496.38 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Glaxosmithkline, LLC. | $156.90 | 2019-2025 | Trelegy Ellipta |
| Electromed, INC. | $102.59 | 2024-2025 | Smartvest |
| Advanced Respiratory, INC | $82.73 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $72.60 | 2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $66.69 | 2024-2025 | Breztri, Airsupra |
| Shionogi INC | $56.92 | 2023-2024 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.30 | 2021 | |
| Paratek Pharmaceuticals, INC. | $24.35 | 2022 | |
| Philips North America LLC | $12.45 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babak Abrishami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.